Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment - Page 24 of 24 Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Phase II clinical trial testing the safety and efficacy of adding entinostat to exemestane therapy in hormone-resistant breast cancer patients

Phase II clinical trial testing the safety and efficacy of adding entinostat to exemestane therapy in hormone-resistant breast cancer patients

Posted by on Jun 5, 2013 in Breast cancer | 0 comments

In a nutshell This phase II clinical trial tested whether a new drug, entinostat, can work in concert with exemestane (a hormone therapy drug), to fight breast cancer that no longer responds to hormone therapy alone. Some background Some breast cancers need estrogen (a female sex hormone) to grow. These breast cancer cells respond to estrogen via...

Read More

Panitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations

Panitumumab combined with irinotecan as a treatment for metastatic colorecatal cancer without KRAS mutations

Posted by on Apr 7, 2013 in Colorectal cancer | 0 comments

In a nutshell This study looks at the use of panitumumab and irinotecan as a combination treatment in patients with KRAS wild-type (non-mutated) metastatic colorectal cancer which has continued to progress while on standard chemotherapy (oxaliplatin, fluoropyrimidines, irinotecan, bevacizumab).   Some background Cancer cells can have...

Read More

Phase III clinical trial for Trametinib shows improved survival in metastatic melanoma patients with BRAF mutations

Phase III clinical trial for Trametinib shows improved survival in metastatic melanoma patients with BRAF mutations

Posted by on Apr 1, 2013 in Melanoma | 0 comments

In a nutshell This study presents the results of a phase III clinical trial evaluating the efficacy and safety of the drug trametinib for the treatment of metastatic melanoma patients with BRAF mutations. Some background BRAF is a protein from a chain of proteins in the cell called the MAP kinase pathway. These play a role in cell division and...

Read More

Phase II clinical trial evaluating the combination of cetuximab and erlotinib for the treatment of patients with metastatic colorectal cancer

Phase II clinical trial evaluating the combination of cetuximab and erlotinib for the treatment of patients with metastatic colorectal cancer

Posted by on Mar 19, 2013 in Colorectal cancer | 0 comments

In a nutshell This article presents the results of a phase II clinical trial that evaluated the efficacy and safety of the combination of two targeted therapies – cetuximab and erlotinib – for patients with metastatic colorectal cancer (mCRC). Some background Colorectal cancer that has spread outside the large...

Read More

Radiofrequency ablation may slow down the progression of metastatic colorectal cancer

Radiofrequency ablation may slow down the progression of metastatic colorectal cancer

Posted by on Mar 5, 2013 in Colorectal cancer | 0 comments

In a nutshell This report aimed to establish if radiofrequency ablation (RFA) of liver metastases originating from colorectal cancer (CRC) provides any benefits to patients with Stage IV of the disease. Main result: RFA extends progression-free survival by 7 months. Some background RFA is a medical procedure for treating patients with small tumors...

Read More

Metastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy

Metastatic colorectal cancer: the benefit of combining cetuximab with chemotherapy

Posted by on Mar 5, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study investigated if patients with spread colorectal cancer that have mutations in the KRAS gene benefit from Cetuximab treatment. Some background Cancer that originates in the colon or rectum (parts of the intestine) is called colorectal cancer (CRC). If the cancer has spread from its original location, beyond the...

Read More

Combining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation

Combining Bevacizumab with chemotherapy for advanced colorectal cancer: efficacy evaluation

Posted by on Feb 25, 2013 in Colorectal cancer | 0 comments

In a nutshell The present study evaluated whether combining Bevacizumab (Avastin) with chemotherapy for patients with stage IV (metastatic) colorectal cancer (CRC) has any benefits in the terms of survival and quality of life. Main findings: Bevacizumab may be beneficial only as part of certain chemotherapy regimens. Some...

Read More

Non-cancerous cells in the prostate contribute to the aquired tumor resistance to chemotherapy

Non-cancerous cells in the prostate contribute to the aquired tumor resistance to chemotherapy

Posted by on Feb 24, 2013 in Prostate cancer | 0 comments

Regretfully, metastatic forms of prostate cancer (spread to distant sites via the blood system) treated with chemotherapy often acquire resistance to the drug, partially due to the repetitive nature of treatment. Resistance leads to tumor progression and treatment failure. This scientific article proposes a novel therapeutic target named WNT16B that...

Read More

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Risks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer

Posted by on Feb 24, 2013 in Colorectal cancer | 0 comments

Colorectal cancer (CRC) often presents with peritoneal metastases, which have a poor outcome. This means that cancer cells have spread from the colon, appendix, or rectum to the peritoneum (a sheath that covers the abdominal organs). This article argues the pros and cons of a combined treatment for patients with peritoneal metastases from CRC. This...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor